The scientific literature provides strong evidence supporting retatrutide's multi-receptor mechanism. A comprehensive Phase 2 human trial demonstrated the peptide's ability to simultaneously engage GLP-1, GIP, and glucagon receptors, with meaningful clinical outcomes in type 2 diabetes management.
Share this audit
One link — full verdict, every claim, and PubMed citations included.
Shareable link includes the full verdict, claims, and PubMed citations.
Post captionshow
R*trutide's Phase 3 data reveals a unique mechanism for weight loss, distinct from other drugs. Understanding its action is key to unlocking its potential.
Video transcriptshow
Retatrutide's phase three trial results just dropped. After actually reading the data myself, I'm not surprised at all. Because for the last 10 weeks, I've been personally experimenting with RETA and I can tell you right now, this is not just a fat loss drug. This is not Ozempic with better marketing. This is definitely not something you can understand through Instagram clips if you never used it …
Show full video transcript
before. As someone who spent years abusing fat burners and stimulants and steroids, Retatrutide is a completely different animal. So in this video, I'm gonna break down the phase three data and what actually it showed because there's parts of this that people are ignoring and why this drug actually behaves differently than semi-glutide and terzeptide. And then I'm gonna walk you through my personal 10-week protocol. I'm gonna talk to you about the dosing, the timing, how I stacked with the other peptides and how I got back down to roughly 8% body fat without wrecking my body and losing my muscle. Let's get into it. Retrutide is a tripital agonist compound, right? So it targets three things, GLP-1, GIP, glucagon. All these receptors are getting hit at the same time. That is a difference right there than your traditional GLP-1s that just suppress your appetite, stop you from eating, and of course you're going to lose weight.
Show lessClaim breakdown
1 claim“Retatrutide targets three receptors: GLP-1, GIP, and glucagon.”
A Phase 2 human clinical trial confirms retatrutide targets GLP-1, GIP, and glucagon receptors, with robust evidence of multi-receptor agonist activity in type 2 diabetes management.
Supporting studies
- 1
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Lancet (London, England) · 2023·PMID 37385280
- 2
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Diabetes care · 2024·PMID 38843460
- 3
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
Proceedings (Baylor University. Medical Center) · 2025·PMID 40291085
- 4
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines
Expert opinion on investigational drugs · 2025·PMID 40022548
- 5
What is the pipeline for future medications for obesity?
International journal of obesity (2005) · 2025·PMID 38302593
- 6
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
Diabetes care · 2024·PMID 38687506
- 7
Gut hormones and appetite regulation
Current opinion in endocrinology, diabetes, and obesity · 2024·PMID 38511400
- 8
Retatrutide-A Game Changer in Obesity Pharmacotherapy
Biomolecules · 2025·PMID 40563436
This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.
Report an error